Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review
Abstract
The global aging population faces an increasing burden of chronic multimorbidity, much of which is driven by inflammaging. Inflammaging is defined as a persistent, low-grade inflammatory state recognized as a hallmark of biological aging. This narrative review examines therapeutic strategies targeting key mechanisms of inflammaging, with particular focus on cellular senescence and the senescence-associated secretory phenotype (SASP), nicotinamide adenine dinucleotide (NAD+) decline, and inflammasome activation. Senolytic therapies designed to eliminate senescent cells have progressed into early-phase clinical trials. Combinations such as dasatinib plus quercetin and the flavonoid fisetin have reduced circulating SASP factors in early studies. Senomorphic agents, including rapamycin and Janus kinase (JAK) inhibitors, represent an alternative strategy by suppressing SASP production while preserving cell viability. Another therapeutic approach focuses on restoring intracellular NAD⁺ levels. Supplementation with precursors such as nicotinamide riboside and nicotinamide mononucleotide has shown beneficial effects on vascular function and metabolic health in early human studies. In addition, inhibition of the NAD⁺-consuming enzyme CD38 represents a complementary strategy aimed at preserving NAD⁺ availability. Targeted anti-inflammatory biologics directed against cytokines such as IL-1β, IL-6, and TNF-α have demonstrated clinical benefits in cardiovascular disease, supporting…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.